Table 2.

Patient clinical descriptions

Clinical description	Group	Number of patients (%)	Total
Follow-up time	60–120 days	7 (21.2%)	33
	≥120 days	26(78.8%)
CMV antigenemia	Positive*	23 (69.7%)	33
	Negative**	10 (30.3%)
CMV disease	Yes	2 (6.1%)	33
	No	31 (93.9%)
Acute GVHD	Grade 0 or I	10 (45.5%)	22
	Grade II to IV	12 (54.5%)
Outcome	Alive at day 120	32 (97.0%)	33
	Death due to CMV disease	none
	Death due to other causes at day 120	1 (3.0%)

CMV: cytomegalovirus; GVHD: Graft-versus-host disease.

^*At least one positive CMV antigenemia assay during the first 120 days of follow-up.

^**No positive antigenemia detected during the first 120 days of follow-up.